New Enterprise Associates related stories
All articles and analysis
Rhythm Metabolic racks up $40 mln Series ABoston-based Rhythm Metabolic, a subsidiary of Rhythm, has closed $40 million in Series A funding. The investors included OrbiMed, Deerfield Management, Wellington Management Company, MPM Capital, New Enterprise Associates, Third Rock Ventures, Pfizer Ventures and Ipsen. In conjunction with the funding, Jonathan Silverstein of OrbiMed has been appointed to Rhythm Metabolic's board of directors. Rhythm Metabolic is focused on treating obesity caused by genetic deficiencies.
- LED maker Illumitex shines with close of Series C
Illumitex, an Austin, Texas-based manufacturer of LEDs, announced it has concluded its C1 round of funding with $16 million. Strategic investor WP Global Partners led the round, which included existing investors New Enterprise Associates, Morgan Creek Capital, Mousse Partners, Apex Venture Partners, DMWMDW Interests, Syngenta Ventures and individual investors Jimmy Treybig and Larry Abrams. The company has now raised $76 million in total funding.
- Virtual storage company Tintri raises $125 mln round led by Silver Lake Kraftwerk
Mountain View, Calif.-based Tintri Inc, a provider of storage for virtualization and cloud environments, announced the close of a $125 million Series F round of funding. Silver Lake Kraftwerk led the round, which included existing investors Insight Venture Partners, Lightspeed Ventures, Menlo Ventures and New Enterprise Associates. The company has now raised $260 million in total funding.
Editor's letter: Don't fall asleep on EuropeIt shouldn’t come as a surprise to VCJ readers that prices are more affordable in Europe, which has a healthy supply of engineers
- NEA leads Series A round for Olio Devices
San Francisco-based watch maker Olio Devices has secured $10 million in Series A funding. New Enterprise Associates led the round.
Data spotlight: M&A deal activity slumps in Q2M&A deals fall in quarter despite LinkedIn’s purchase of Lynda.com pushing the combined value above $4 billion
- Ra Pharmaceuticals racks up $58.5 mln Series B
Cambridge, Massachusetts-based biotech company Ra Pharmaceuticals has closed $58.5 million in Series B funding. RA Capital Management, Novo Ventures and Lightstone Ventures led the round with participation from other investors that included Rock Springs Capital Limulus Venture Partners, New Enterprise Associates, Novartis Venture Fund, Morgenthaler Ventures and Amgen Ventures. In conjunction with the funding, Rajeev Shah of RA Capital and Peter Tuxen Bisgaard of Novo Ventures (US) Inc have been added to Ra Pharma’s board of directors.
- Apprenda snags $24 mln
Apprenda, a Platform as a Service solutions provider, has raised $24 million in funding. Safeguard Scientifics led the round with participation from New Enterprise Associates and Ignition Partners.
Mid-sized funds bring solid results to Hawaiian portfolio--VCJ fund performance reportFunds from MPM, Canaan, Polaris and Battery rank as top holdings in Hawaii ERS portfolio.
Venture capital on pace for largest investment year since 2000Venture capital continued to flow to U.S. startups at a fast pace in the second quarter with dollars invested up 24 percent and pre-money valuations holding pretty steady from the fourth quarter at an elevated $65 million.